308468
Visual impairment and age-related eye diseases
Among US adults 18 years and older, 61.8% reported wearing glasses or contact lenses. The estimated age-adjusted prevalence for VI and selected ED were: VI – 11%, cataract – 10.5%, glaucoma - 2.2%, macular degeneration - 1.6%, and diabetic retinopathy – 0.6%. The prevalence of diabetic retinopathy among persons with diabetes was 6.2%. About 31.9% of persons with cataract, 26.6% of persons with glaucoma, 39.3% of persons with macular degeneration, and 55.7% of persons with diabetic retinopathy reported having VI. The prevalence of ED increased significantly with increasing age, particularly in people over age 65. Age-adjusted prevalence of ED was higher among women, adults with diabetes, adults with low income, and adults with less than a high school education than their respective counterparts.
VI affects quality of life with more than 20% of visually impaired adults reported having difficulties with daily activities such cooking, fixing things around the house, reading newspapers, and driving even when wearing glasses or contact lenses.
The study provides nationally representative data on self-reported VI, selected eye diseases, and activity limitations due to VI to inform development of targeted public health initiatives to support those with VI.
Learning Areas:
Implementation of health education strategies, interventions and programsPublic health or related education
Public health or related public policy
Learning Objectives:
Identify the prevalence of visual impairment and eye diseases among the US population.
Analyze the socioeconomic and demographic characteristics associated with increased likelihood for visual impairment and eye diseases.
Keyword(s): Vision Care, Healthy People 2020
Qualified on the content I am responsible for because: I am an epidemiologist and have worked on vision data for many years. I conducted the analysis and wrote this abstract.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.